Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 602-605

  Kao, Steven Chuan Hao ^a,b   Yan, Tristan D ^c,d   Lee, Kenneth ^d   Burn, Juliet ^e   Henderson, Douglas W ^f   Klebe, Sonja ^f   Kennedy, Catherine ^g   Vardy, Janette ^b,g   Clarke, Stephen ^a,b   Van Zandwijk, Nico ^a   McCaughan, Brian C ^c,d  

^a Bernie Banton Centre   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Department of Geriatric Medicine   (Australia)

^e Davies Campbell de Lambert Pathology   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biphasic mesothelioma; Diagnosis; Epithelial mesothelioma; Malignant pleural mesothelioma

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL PNEUMOTHORAX; BIOPSY; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORACOSCOPY; THORACOTOMY;

EID: 79951770249     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820ce2c7     Document Type: Article

References (13)

1. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
2. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718-721.
3. Kazan-Allen L. Killing the Future-Asbestos Use in Asia. London: IBAS, 2007. Pp. 8-20.
4. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
5. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731. (Pubitemid 28130949)
6. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
7. Symanowski J, Rusthoven J, Nguyen B, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed- cisplatin vs. cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22:abstract 2602.
8. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62(Suppl 2):ii1-ii19.
9. Stahel RA, Weder W, Felip E, On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2):ii43-ii44.
10. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110: 2248-2252. (Pubitemid 350100747)
11. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004;78:1774-1776. (Pubitemid 39423553)
12. Aisner J. Diagnosis, staging, and natural history of pleural mesothelioma. In: J Aisner (Ed.), Comprehensive Textbook of Thoracic Oncology. Baltimore, MD: Williams and Wilkins, 1996. Pp. 799-785.
13. Yan T, Boyer M, Tin M, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.